Vega Therapeutics launches and unveils its first-in-class antibody therapy for von Willebrand disease at ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders, today announced its launch and oral presentation of its first-in-class antibody therapy, VGA039, at the 64th American Society of Hematology (ASH) Annual Meeting. Vega was spun out of its parent company,...
